Polycystic ovary syndrome--from gynaecological curiosity to multisystem endocrinopathy

Homburg, Roy

doi:10.1093/oxfordjournals.humrep.a019031

Cited by 191 publications

(105 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At one extreme of this range are women phenotypically normal, eumenorrheic, with no signs of hyperandrogenism, but with ultrasonographically-appearing PCO. At the other end are women who have full-blown expression of the syndrome (23). In the middle, one can find different clinical entities with the common ultrasonographic findings.…”

Section: Discussionmentioning

confidence: 99%

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Cano

García-Velasco

Millet

et al. 1997

J Assist Reprod Genet

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Cano

García-Velasco

Millet

et al. 1997

J Assist Reprod Genet

View full text Add to dashboard Cite

“…Criteria for PCOS were as defined by Homburg (14). All subjects had polycystic ovaries as shown by vaginal ultrasonography (eight or more subcapsular follicles of 3 -8 mm diameter in one plane in one ovary and increased stroma) and at least one of the following symptoms: oligomenorrhea or amenorrhea, clinical manifestations of hyperandrogenism such as hirsutism scored (.…”

Section: Subjectsmentioning

confidence: 99%

Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

et al. 2005

View full text Add to dashboard Cite

Objective: Women with polycystic ovary syndrome (PCOS) exhibit risk factors for cardiovascular diseases such as abdominal obesity, insulin resistance and dyslipidemia. Insulin sensitizers, especially metformin, have been shown to improve these metabolic disturbances, but there are only a few studies on their effects on serum lipids in polycystic ovary syndrome. Methods: Thirty-five women with PCOS (18 obese and 17 non-obese) were randomized to 6-month treatments with metformin or ethinyl estradiol -cyproterone acetate oral contraceptive pills. Results: In the whole-study population (non-obese and obese women) serum levels of high-density lipoprotein cholesterol increased from 1.4^0.2 to 1.6^0.1 mmol/l (means^S.E. throughout) at 3 and 6 months (P , 0.001), the total cholesterol:high-density lipoprotein cholesterol ratio decreased significantly from 3.8^0.3 to 3.3^0.2 at 6 months (P , 0.001) and a similar trend was observed in serum triglyceride levels during metformin treatment. In the oral contraceptive group, serum levels of total cholesterol increased from 4.9^0.3 to 5.4^0.3 mmol/l (P , 0.05), high-density lipoprotein cholesterol increased from 1.2^0.1 to 1.5^0.1 mmol/l (P , 0.001), the total cholesterol:high-density lipoprotein cholesterol ratio decreased from 4.6^0.4 to 3.7^0.2 (P , 0.001) and triglycerides increased from 1.3^0.1 to 1.9^0.2 mmol/l at 6 months of treatment (P , 0.001). Serum low-density lipoprotein cholesterol levels remained unchanged during both treatments. Milder but similar changes in the subgroups of obese and non-obese women were observed during both treatments. Moreover, in the whole-study population both systolic (P ¼ 0.02) and diastolic (P ¼ 0.05) blood pressures decreased over the 6 months of metformin treatment. Conclusion: In women with PCOS, metformin treatment had beneficial effects on lipid profile and blood pressure, and therefore it could be useful in the prevention of cardiovascular complications in these women. 152 269-275 European Journal of Endocrinology

show abstract

“…The duration of this treatment for at least 6 months is related to the long physiological duration of the hair follicle, while the effect on acne is faster [46].…”

Section: Pathophysiology -Altered Physiological Statesmentioning

confidence: 99%

Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications

Alsadi¹

2018

Pathophysiology - Altered Physiological States

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. The clinical picture characterized by both endocrine disorders (hyperandrogenism, menstrual cycle disorders, obesity) and metabolic alteration with implications for women's health and reproductive and metabolic consequences. Leventhal described for the first time a syndrome characterized by polycystic ovaries associated with menstrual cycle disorders, hirsutism, and obesity. The pathophysiology and other metabolic disorders that make the PCOS more complex than originally described are the most common cause of infertility linked to chronic anovulation. In fact, this is a multifactorial disorder that involves the hypothalamus, pituitary, ovary, adrenal, and peripheral adipose tissues, which are simultaneously involved in the pathogenesis of the syndrome.

show abstract

Polycystic ovary syndrome--from gynaecological curiosity to multisystem endocrinopathy

Cited by 191 publications

References 124 publications

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women

Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications

Contact Info

Product

Resources

About